410 related articles for article (PubMed ID: 17373219)
21. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
22. Fabry disease: cardiac manifestations and therapeutic options.
Pierre-Louis B; Kumar A; Frishman WH
Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
[TBL] [Abstract][Full Text] [Related]
24. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
25. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
26. [Fabry disease--a provocation for pediatrics].
Hoffmann B; Mayatepek E
Klin Padiatr; 2006; 218(1):38-40. PubMed ID: 16432775
[TBL] [Abstract][Full Text] [Related]
27. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
[TBL] [Abstract][Full Text] [Related]
28. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
[TBL] [Abstract][Full Text] [Related]
29. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
[TBL] [Abstract][Full Text] [Related]
30. [Two cases of heterozygous Fabry disease].
Shibuya Y; Oku N; Suzuki Y; Gomi T
Nihon Jinzo Gakkai Shi; 2006; 48(5):421-7. PubMed ID: 16913464
[TBL] [Abstract][Full Text] [Related]
31. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
32. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
33. [Fabry disease in Italy: first epidemiologic and collaborative study].
Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
[TBL] [Abstract][Full Text] [Related]
34. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
35. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
[TBL] [Abstract][Full Text] [Related]
36. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
37. [Fabry's disease; towards a treatment].
Linthorst GE; Hollak CE; Bosman DK; Heymans HS; Aerts JM
Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2391-5. PubMed ID: 11145093
[TBL] [Abstract][Full Text] [Related]
38. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
39. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
40. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.
Schiffmann R
Acta Neurol Belg; 2006 Jun; 106(2):61-5. PubMed ID: 16898255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]